Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Spliceosome mutations in AML: Prevalence, clinical features, and treatment outcomes in a contemporary cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

EZEmily C. ZaborMAMoath AlbliwiABAmeed Bawwab

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis reveals spliceosome mutations in AML may show limited prognostic significance in outcomes.

Key Points

  • Patients with spliceosome mutations in acute myeloid leukemia showed no significant differences in clinical outcomes, despite variable baseline characteristics.
  • A total of 971 AML patients were evaluated, with 68% of SRSF2 mutations found in male patients compared to 54% of wild type.
  • Analysis of mutations used multivariable logistic and Cox proportional hazards models to adjust for demographic and genetic variables.
  • Future multi-institutional research is needed to confirm the prognostic relevance of these mutations in AML.

Cite This Study

Zabor et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da5ahttps://doi.org/10.1182/blood-2025-3396
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical outcomes in spliceosome-mutant myelodysplastic neoplasms and Acute Myeloid Leukemia2025
  2. 2Epigenetic dysregulation of the polycomb axis in Acute Myeloid Leukemia: Clinical and prognostic correlates2025
  3. 3Additional myelodysplasia-related genes mutations affected the clinical presentations and prognosis of patients with SRSF2/TET2 co-mutations2025
  4. 4Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWP2025
  5. 5Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.2025